Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CM24
    • NT219
    • IM1240
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Author: Steven Epstein

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech will present a poster titled: ‘Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil Extracellular Traps (NETs)’ at the AACR Special Conference: Pancreatic Cancer, September 27-30, 2023. Presentation date and time: September 28 at 4:40 pm, 2023
  • Drug Discovery World article on NT219 poster publication on AACR23: “New drug could help overcome tumour resistance to treatment”
  • NT219 induces tumor PD-L1 expression and potentiates anti-PD-1efficacy
  • Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
  • Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.
  • Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
  • Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
  • Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
  • Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
  • Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.

Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.

By afri-can
in
Events
Apr 18, 2023
Read more
Purple Biotech Presents NT219 Pre-Clinical Data at the  AACR 2023 Annual Meeting.

Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.

By afri-can
in
Events
Apr 16, 2023
Read more
Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.

Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.

By afri-can
in
News
Mar 27, 2023

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies

Read more
Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.

Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.

By afri-can
in
Events
Mar 20, 2023

March 20 2023 at 8:00 am – March 22 at 5:00 pm – UTC+0

Read more
Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.

Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.

By afri-can
in
News
Mar 14, 2023

EXECUTIVE INTERVIEW – Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies

Read more
Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.

Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.

By afri-can
in
Events
Feb 01, 2023

February 6 2023 at 8:00 am – February 7 at 5:00 pm – UTC+0

Read more
Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023

Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023

By afri-can
in
Events
Dec 11, 2022

January 9 2023 at 8:00 am – January 12 at 5:00 pm – UTC+0

Read more
Purple Biotech to participate and Present at the Jefferies London Healthcare Conference

Purple Biotech to participate and Present at the Jefferies London Healthcare Conference

By afri-can
in
Events
Nov 11, 2022

November 15 2022 at 8:00 am – November 17 at 5:00 pm – UTC+0

Read more
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis 

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis 

By afri-can
in
Events
Nov 08, 2022

November 14 2022 at 8:00 am – November 17 at 5:00 pm – UTC+0

Read more
Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay

Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay

By afri-can
in
Events
Nov 01, 2022

November 8 2022 at 8:00 am – 5:00 pm – UTC+0

Read more
1 2 Next »
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2021 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset